About Us
About MiReven
miReven Pty Ltd is an Australian-based biotechnology company specialising in the design, development and commercialisation of synthetic mimics of microRNA-7 (miR-7) for the treatment of poor prognostic cancers. The company was initially established in 2010, following investment from the Medical Research Commercialisation Fund (MRCF), University of Western Australia (UWA), and the Harry Perkins Institute of Medical Research.
MiReven Pty Ltd was formed in 2010 through an investment from the Medical Research Commercialisation Fund (MCRF). The company is commercialising the pioneering work of Prof Peter Leedman and Dr Keith Giles at the Harry Perkins Institute for Medical Research on the anti-cancer potential of miR-7. The Perkins Institute’s published research shows that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signaling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.
The Perkins Institute was assisted in the commercialisation of its intellectual property by the University of Western Australia, through its Office of Industry and Innovation. Founding board members included Mr John Fitzgerald, Ms Samantha South, and Mr Steven Thompson.
In 2018 MiReven was relaunched solely by Professor Peter Leedman in response to significant breakthroughs in RNA therapeutics internationally and some seminal results in his laboratory for cancer medicine.
About The Medical Research
Commercialisation Fund (MRCF)
The $51 million Medical Research Commercialisation Fund (MRCF) Collaboration is an innovative investment collaboration established in 2007 and managed by Brandon Capital Partners (www.brandoncapital.com.au). The MRCF invests in early stage development and commercialisation opportunities emanating from its membership of 32 Australian medical research institutes and allied research hospitals, which includes the Harry Perkins Institute for Medical Research. The MRCF IIF, LP fund is supported by AustralianSuper, StatewideSuper and the Australian Government under its IIF program. The MRCF also acknowledges the support of the State Governments of Victoria, New South Wales, Western Australia and Queensland.
www.mrcf.com.au
About The University
of Western Australia (UWA)
Established in 1911, UWA is a research-intensive university ranked 93 in the world, 56.6 for Life & Agricultural Sciences and 42.6 for Clinical Medicine & Pharmacy, in the highly respected Shanghai-Jiao Tong University’s Academic Ranking of World Universities in 2018. As Western Australia’s premier university, UWA is a member of the prestigious ‘Group of Eight’-a coalition of the top research universities in Australia- and one of only two Australian universities to belong to the Worldwide Universities Network, a partnership of 18 research-led universities from Europe, North America, North Asia, Australia and Africa. The commercialisation of WAIMR intellectual property is facilitated through UWA’s Office of Industry & Innovation.
www.uwa.edu.au
Giving hope to patients with poor prognostic cancers
Advancing the next generation of RNA-based therapeutics
Company Overview
Our Mission
Development of a novel RNA-based drug mRx-7 for treatment of solid tumors.
Our Vision
Our Values
Our Team
miReven is commercialising the pioneering work of Prof Peter Leedman and Dr Keith Giles at the Harry Perkins Institute of Medical Research on the anti-cancer potential of miR-7.